PASADENA NEUROPSYCHIATRY CENTER A MEDICAL CORPORATION

What PASADENA NEUROPSYCHIATRY CENTER A MEDICAL CORPORATION does

Pasadena Neuropsychiatry Center A Medical Corporation is a physician-led interventional psychiatry practice founded in 2019 in Pasadena, California, by Dr. Torie Sepah. The practice specializes in treatment-resistant mood and anxiety disorders, delivering non-invasive and novel pharmacologic interventions including BrainsWay Deep Transcranial Magnetic Stimulation (dTMS), the Stanford SAINT Protocol for accelerated TMS, Janssen's Spravato (esketamine intranasal), Sage Therapeutics' Zulresso (brexanolone IV infusion) for postpartum depression, and Myriad Genetics' GeneSight pharmacogenomic testing to guide medication selection. The clinic reports a cumulative caseload of 20,000–25,000+ TMS treatments performed since inception and maintains a 4.8/5 Google rating across 79+ reviews.

The business operates a single-site clinical model with approximately 5 employees, generating revenue through per-session and per-treatment pricing: TMS at roughly $200/session, Spravato at $1,450–$1,742 per session, and diagnostic evaluations at $350–$500. Reimbursement is secured through in-network contracts with six major payors — Aetna, Anthem/Blue Cross, Cigna, Magellan, Optum/United, and Medicare — supplemented by out-of-pocket and out-of-network revenue. The practice holds several restricted designations that materially shape its market position, including BrainsWay Premium Provider status, Janssen Spravato Center designation, and limited LA-area REMS certification for Zulresso.

Beyond direct patient care, the practice has invested in ecosystem and pipeline assets: it co-founded the Physician to Physician network spanning 400,000+ physicians and hosts psychiatry residents from PIH Downey Hospital, building referral channels and a clinician training pipeline. The go-to-market is predominantly consumer- and referral-driven rather than enterprise- or payer-driven, with physician reputation, vendor designations, and clinical outcomes serving as the primary demand-generation levers.

Name

PASADENA NEUROPSYCHIATRY CENTER A MEDICAL CORPORATION

Legal name

Pasadena Neuropsychiatry A Medical Corporation

Website

https://toriesepahmd.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

Pasadena Neuropsychiatry Center is a Pasadena, California interventional psychiatry practice founded in 2019 that delivers Deep TMS, Spravato, Zulresso, and SAINT Protocol treatments to patients with treatment-resistant mood and anxiety disorders.

Ownership category

akta.pro rank

Product category

Interventional Psychiatry Services

NAICS

Offices of Physicians, Mental Health Specialists (621112), Outpatient Mental Health and Substance Abuse Centers (621420)

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011)

akta.pro primary industry

General Neurology (HLAKAIAA)

akta.pro secondary industry

Cognitive & Behavioral Neurology (Dementia/Memory Disorders) (HLAKAIAH)

Keywords

• Interventional psychiatry
• Transcranial magnetic stimulation
• Treatment-resistant depression
• Esketamine treatment
• Reproductive psychiatry

Headquarters

HQ city

Pasadena

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. TMS Treatment Procedures: Revenue from deep TMS (dTMS) treatments including mapping, treatment sessions, and remapping. Both insurance-covered and cash-pay options available. The clinic has completed over 20,000 TMS treatments since 2019.
2. Spravato (Esketamine) Treatments: Revenue from Spravato/esketamine nasal spray treatments at two dosage levels (56mg and 84mg). Covered by Medicare and other insurance plans.
3. Psychiatric Evaluation and Medication Management: Office visits including initial evaluations and follow-up appointments for psychiatric care, both in-person and via telemedicine. Accepts multiple insurance carriers and offers cash-pay rates.
4. GeneSight Genetic Testing: Out-of-pocket pharmacogenomic testing at $175 per test, not covered by insurance.
5. Zulresso (Brexalone) Treatment: Inpatient postpartum depression treatment requiring medical monitoring, one of only a few providers in Southern California.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels8 records

Core offering

Pasadena Neuropsychiatry is an interventional psychiatry medical practice that delivers FDA-cleared BrainsWay Deep Transcranial Magnetic Stimulation (dTMS), Spravato (esketamine) nasal spray therapy, Zulresso (brexanolone) inpatient treatment, and the SAINT Protocol TMS for patients with treatment-resistant depression, OCD, postpartum depression, and acute suicidal ideation. The practice supplements neuromodulation with GeneSight pharmacogenomic testing, personalized medication management, and reproductive psychiatry services for women across life stages.

Product overview

Pasadena Neuropsychiatry is an interventional psychiatry practice offering a comprehensive portfolio of FDA-approved neuromodulation and pharmacological treatments for mental health conditions. The core offerings center around BrainsWay dTMS technology (with both standard rTMS and Theta Burst protocols) for depression, OCD, and related conditions, supplemented by Spravato (esketamine) and Zulresso (brexanolone) for treatment-resistant and postpartum depression. The practice also provides GeneSight pharmacogenomic testing for personalized medication selection and general psychiatric services. All treatments are integrated within a patient-centered care model emphasizing evidence-based interventions.

Differentiator

Problem solved

Functional benefit

Brands

• dTMS (Deep TMS): Deep Transcranial Magnetic Stimulation treatment using BrainsWay technology for depression, OCD, and other conditions.

Products and services

• BrainsWay Deep TMS (dTMS) Non-invasive deep Transcranial Magnetic Stimulation using BrainsWay's proprietary H1 coil to stimulate deep brain structures; FDA-cleared for treatment-resistant depression, OCD, anxious depression, smoking cessation, and late-life depression (adults 68-86 years). Delivered to adult patients with treatment-resistant mental health conditions.
• Theta Burst dTMS Three-minute theta burst TMS protocol using the BrainsWay dTMS system, FDA-cleared for Major Depressive Disorder, Treatment-Resistant Depression, and Anxious Depression with shorter session duration.
• SAINT Protocol TMS Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) Protocol using accelerated TMS for acute suicidal ideation, showing approximately 80% effectiveness in controlled studies. Available for patients in psychiatric crisis.
• Spravato (Esketamine) Treatment Janssen-designed esketamine nasal spray treatment for treatment-resistant depression and postpartum depression, administered at two dosage levels (56mg and 84mg). Covered by Medicare and other insurance.
• Zulresso (Brexanolone) Treatment FDA-approved brexanolone intravenous treatment for postpartum depression requiring inpatient administration with medical monitoring. One of the only providers in the Los Angeles area.
• GeneSight Pharmacogenomic Testing Non-invasive pharmacogenomic genetic test through GeneSight (Myriad Genetics) that analyzes a patient's DNA to predict response to psychiatric medications, helping clinicians choose the most effective medications early in treatment. Out-of-pocket $175 per test.
• Reproductive Psychiatry Specialized psychiatric care for women across reproductive life stages, including postpartum depression, postpartum psychosis, premenstrual dysphoric disorder (PMDD), perimenopause, and menopause mood disorders, with bio-identical hormones and hormone replacement therapy.
• General Psychiatry Evaluation and Medication Management Comprehensive psychiatric evaluation, diagnosis, and medication management for depression, anxiety disorders, schizophrenia, OCD, and other mental health conditions, delivered in-person and via telemedicine.

Quantifiable outcome

• 60% remission rate with dTMS and medication vs. 11% with medication alone
• +4 more outcomes

Named customers3 records

Segments5 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

Feature7 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• BrainsWaycoreTechnology or IntegrationBrainsWay is the technology provider for deep TMS (dTMS) systems used by Pasadena Neuropsychiatry. The practice is a BrainsWay Premium badge holder (highest tier). The partnership provides exclusive access to BrainsWay's H1 coil technology — the only TMS system FDA-cleared for OCD and late-life depression (68-86 years). The practice has completed over 20,000 BrainsWay TMS treatments since 2019.
• Janssen PharmaceuticalscoreTechnology or IntegrationPasadena Neuropsychiatry is a Janssen-designated Spravato Center for administering esketamine (Spravato) nasal spray. This designation indicates an authorized treatment center relationship with Janssen Pharmaceuticals for their Spravato product. Medicare and other insurance cover Spravato treatments at this center.
• PIH Downey HospitalminorStrategic or Co-development PartnerPasadena Neuropsychiatry has become a learning facility where third-year family medicine residents from PIH Downey Hospital complete their four-week psychiatry/substance abuse clerkships. Residents gain hands-on experience with psychiatric conditions and treatments while providing care to patients under supervision.
• International Society of Reproductive HealthminorOthersDr. Sepah is a member of the International Society of Reproductive Health, which provides her with current research and best practices in reproductive mental health to inform her evidence-based treatments for women at various stages of life.
• Soft White Underbelly / Dr. PhilminorGTM or Marketing PartnerDr. Sepah has been featured as an expert on postpartum psychosis on Soft White Underbelly and Dr. Phil platforms. She treated Carol Coronado, featured in the documentary 'Not Carol,' contributing to awareness of postpartum psychosis. These media appearances build professional reputation and patient trust.
• Kevin MDminorGTM or Marketing PartnerDr. Sepah has authored multiple articles on Kevin MD platform covering physician burnout, MOC, language in healthcare, and normalizing psychiatric care. Kevin MD is a leading healthcare social platform amplifying physician voices.
• Physician to PhysicianminorOthersCo-founded by Dr. Sepah, Physician to Physician is a physician community platform with over 400,000 members offering peer support for physician burnout and medical practice challenges. The platform generates professional referrals and establishes Dr. Sepah as a thought leader.

Scale indicators7 records

Recent moves7 records

Expansion highlights4 records

Broad incumbents

• Neuronetics (NeuroStar): Manufacturer of the NeuroStar TMS system and operator of affiliated treatment centers. A larger incumbent with overlapping capabilities in the TMS category that competes for the same patients and physician providers.
• BrainsWay: Manufacturer of the dTMS system used by Pasadena Neuropsychiatry. While primarily a device vendor, BrainsWay also supports partner clinics and represents the technology platform on which the practice's differentiation rests.
• Amen Clinics: Multi-site psychiatric practice using brain imaging (SPECT) combined with medication management and interventional treatments. A larger incumbent with comparable neuropsychiatric positioning and premium cash-pay model.

Direct peers

• Bespoke Treatment: Interventional psychiatry practice offering TMS, ketamine, and Spravato for treatment-resistant depression and related conditions. Comparable service mix and interventional focus, based in the western US.
• TMS Centers of America: Network of TMS treatment centers offering BrainsWay dTMS and Spravato for treatment-resistant depression. Directly comparable in modality mix and interventional positioning.
• Mindful Health Solutions: California-based interventional psychiatry practice offering TMS, esketamine, and medication management across multiple locations. Closely comparable in service mix (dTMS, Spravato) and California geography.
• Pacific Mind Health: Southern California interventional psychiatry practice offering TMS, Spravato, and integrative mental health services. Directly comparable regional peer competing in the same LA-area market.
• Kadima Neuropsychiatry: San Diego-based interventional psychiatry practice offering dTMS, Spravato, and personalized medication management. Closely comparable in treatment-resistant focus and California presence.
• Greenbrook TMS Inc. Largest US provider of TMS therapy with hundreds of treatment centers across multiple states. Directly comparable as a TMS-focused interventional psychiatry operator, though Greenbrook operates at much greater scale and uses primarily NeuroStar devices.

Emerging players

• Psychiatric Wellness Center (Dulce Mental Wellness): Smaller interventional psychiatry practice offering TMS and ketamine-based treatments for depression. Comparable in treatment-resistant focus and interventional offerings, operating at a smaller scale.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/drsepah
• Instagraminstagram.com/toriesepahmd
• LinkedInlinkedin.com/company/pasadena-neuropsychiatry-center-a-medical-corporation

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PASADENA NEUROPSYCHIATRY CENTER A MEDICAL CORPORATION